Multi-Gene Liquid Biopsy Breast Cancer Panel

Biocept Inc Logo
Biocept Logo (PRNewsFoto/Biocept, Inc.)

Liquid biopsy test provider Biocept has announced Target Selector NGS Breast Panel, a multi-gene liquid biopsy panel specifically developed for breast cancer. The Target Selector NGS Breast Panel—which runs on Thermo Fisher Scientific’s Ion Torrent NGS platform—combines Biocept’s expertise in blood sample preservation and DNA/RNA isolation, with Thermo Fisher’s NGS panel and its Oncomine informatics technology. Molecular profiling determines the status of actionable biomarkers such as ER, PR, and HER2 to guide clinicians in their treatment selection for women with breast cancer. The company’s technology allows monitoring of biomarker status in patients with metastatic breast cancer using the 12-gene Target Selector NGS Breast Panel, or the Target Selector single biomarker tests leveraging Biocept’s proprietary circulating tumor DNA (ctDNA) or recently expanded circulating tumor cell (CTC) detection platforms.


This site uses Akismet to reduce spam. Learn how your comment data is processed.